Page 80 - Priority Review News Today

/PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") partner Everest Medicines (HKEX 1952.HK) today announced that the Center for Drug Evaluation...

STOCKHOLM, Dec. 30, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") partner Everest Medicines (HKEX 1952.HK) today announced that the Center for Drug Evaluation (CDE) of

The FDA has accepted for Priority Review the NDA for RiVive (naloxone intranasal) as an over-the-counter emergency treatment for opioid overdose.

/PRNewswire/ -- Harm Reduction Therapeutics (HRT), Inc., a 501(c)(3) nonprofit pharmaceutical company whose mission is to prevent opioid overdose deaths by...

/PRNewswire/ -- Harm Reduction Therapeutics (HRT), Inc., a 501(c)(3) nonprofit pharmaceutical company whose mission is to prevent opioid overdose deaths by...

Genmab has filed a JNDA with the MHLW of Japan for subcutaneous epcoritamab to treat relapsed/refractory (R/R) large B-cell lymphoma (LBCL) patients.

Investegate announcements from AstraZeneca PLC, Lynparza approved in EU for prostate cancer

AstraZeneca and MSD's Lynparza approved in the EU for prostate cancer

This Week in Washington: All Efforts Are on Funding the Government Through the Rest of the Fiscal Year...

The first gene therapy for high-risk non-muscle-invasive bladder cancer has been approved by The US Food and Drug Administration (FDA).